Compare BV & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BV | PCRX |
|---|---|---|
| Founded | 1939 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2018 | 2010 |
| Metric | BV | PCRX |
|---|---|---|
| Price | $12.14 | $36.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 9 |
| Target Price | $15.35 | ★ $33.57 |
| AVG Volume (30 Days) | 813.3K | ★ 2.3M |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $3.21 | $3.84 |
| Revenue Next Year | $0.18 | $4.73 |
| P/E Ratio | ★ N/A | $191.58 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $9.82 | $18.80 |
| 52 Week High | $15.00 | $36.67 |
| Indicator | BV | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.26 | 83.12 |
| Support Level | $11.47 | $21.97 |
| Resistance Level | $12.59 | $36.45 |
| Average True Range (ATR) | 0.33 | 0.09 |
| MACD | 0.19 | -0.28 |
| Stochastic Oscillator | 92.68 | 25.35 |
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.